Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaOmid Hamid, Antoni Ribas, Caroline Robert et al.|New England Journal of Medicine|2013Cited by 3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Adil Daud, Peter D. Boasberg et al.|The Lancet|2014Cited by 1.8k
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Clinical Cancer Research|2018Cited by 311
Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with PembrolizumabRichard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Clinical Cancer Research|2018Cited by 38
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.Richard W. Joseph, Tara C. Gangadhar, Jeroen Elassaiss‐Schaap et al.|Journal of Clinical Oncology|2014Cited by 35